Eleni Kampouraki

Suggest Changes
Learn More
e14027 Background: To evaluate the safety and efficacy of cetuximab combined with 5FU/LV, irinotecan and oxaliplatin (FOLFOXIRI) as initial treatment for patients with unresectable, KRAS wt mCRC. (More)
  • 1